The American vaccine against COVID-19 showed an effectiveness of almost 95%



[ad_1]

The American biotechnology company Moderna has announced its intention to apply to the United States Food and Drug Administration in the coming weeks to obtain approval for the use of the mRNA-1273 vaccine against COVID-19 coronavirus infection in situations of emergency.

The vaccine against the coronavirus infection COVID-19, which was developed by the American biotechnology company Moderna, showed an effectiveness of 94.5% in the third stage of trials. This is stated in a statement posted on the company’s website on November 16.

The trials involved 30 thousand people, two weeks after vaccination, 95 study participants became ill, 90 of them received a placebo.

Moderna intends to apply to the US Food and Drug Administration (FDA) in the coming weeks for approval of an emergency vaccine. The FDA will evaluate the vaccine based on the observation of 151 participants in the two-month trials, according to the statement.

The company plans to produce 20 million doses by the end of 2020 for shipment to the United States and 500 million to 1 billion doses in 2021 for sale in other countries.

Modern reported successful completion of the second phase clinical trials in mid-July. 45 people between 18 and 55 years old attended. Third, last test phase MRNA-1273 started on July 27.

According to the World Health Organization, as of November 3, 47 COVID-19 vaccine manufacturers worldwide are candidates for clinical evaluation of the produced vaccine. 155 companies are conducting preclinical trials.

The US company Pfizer announced on November 9 that the COVID-19 BNT162b2 vaccine, developed in conjunction with the German BioNTech, has shown an effectiveness greater than 90% in the third phase of clinical trials. The company is still investigating. The director of the World Health Organization, Terdros Adhanom Ghebreyesus, described the vaccine as “very promising.”

He believes that the vaccine alone will not stop the COVID-19 pandemic.

“We will still need to continue surveillance, testing, isolation and care, tracing and locating [контактных лиц] quarantine; involving communities, urging people to be careful, “said the WHO chief.



[ad_2]